湖南汉森制药股份有限公司2025年半年度报告摘要

Core Points - The company, Hunan Hansen Pharmaceutical Co., Ltd., held its sixth board meeting on August 22, 2025, where it approved the 2025 semi-annual report and the appointment of a new securities affairs representative [10][11][14]. Group 1: Company Overview - Hunan Hansen Pharmaceutical Co., Ltd. is committed to ensuring the authenticity, accuracy, and completeness of its information disclosure [8]. - The company has not changed its controlling shareholder or actual controller during the reporting period [4][5]. Group 2: Financial and Operational Highlights - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [2]. - The semi-annual report and its summary were published on designated information disclosure platforms [11]. Group 3: Management Changes - The board appointed Ms. Tang Lifeng as the securities affairs representative, effective from the date of the board's approval until the end of the current board's term [14]. - Ms. Tang holds a bachelor's degree in financial management and has been with the company since October 2024 [9].